MedPath

A study on Acarbose and Myo-inositol combination therapy on the complications of PCOS.

Phase 3
Conditions
Health Condition 1: E89-E89- Postprocedural endocrine and metabolic complications and disorders, not elsewhere classified
Registration Number
CTRI/2022/04/041877
Lead Sponsor
SRM College of Pharmacy SRM Institute of Science and Technology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

a) Subjects diagnosed with PCOS based on Rotterdam criteria such as chronic anovulation- oligomenorrhea or amenorrhea, clinical or biochemical hyperandrogenism, polycystic ovarian morphology by transvaginal ultrasound.

b) Subjects with IR ( fasting glucose: insulin ratio < 4.5)

c) Subjects with aged 18 to 39

d) Subjects with BMI > 25

e) Subjects with willingness to provide informed consent will be included in the study.

Exclusion Criteria

a) Subjects with diseases and conditions that mimic PCOS such as Cushing syndrome, congenital adrenal hyperplasia, idiopathic hirsutism, prolactinoma, acromegaly, type 2 DM, ovarian and adrenal androgen secreting tumours.

b) Subjects on Oral contraceptives, glucocorticoids, antiandrogen, ovulation induction tablets, anti-diabetes, anti-obesity drugs for the past 3 months will be excluded from the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath